Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The Burden of Severe Respiratory Syncytial Virus Disease Among Children Younger than 1 Year in Central and Eastern Europe.

Van de Steen O, Miri F, Gunjaca M, Klepac V, Gross B, Notario G, Wegzyn CM.

Infect Dis Ther. 2016 Jun;5(2):125-37. doi: 10.1007/s40121-016-0109-y.

2.

Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.

Möller J, Desai K, Simpson K, Baran RW, Van de Steen O, Dietz B, Gooch K.

J Med Econ. 2014 Apr;17(4):250-8. doi: 10.3111/13696998.2013.877469.

PMID:
24351091
3.

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

SECOND-LINE Study Group., Boyd MA, Kumarasamy N, Moore CL, Nwizu C, Losso MH, Mohapi L, Martin A, Kerr S, Sohn AH, Teppler H, Van de Steen O, Molina JM, Emery S, Cooper DA.

Lancet. 2013 Jun 15;381(9883):2091-9. doi: 10.1016/S0140-6736(13)61164-2.

PMID:
23769235
4.

Supplemental Content

Loading ...
Support Center